Effect of NF-κB constitutive activation on proliferation and apoptosis of gastric cancer cell lines

European Surgical Research

Volumn 37, Issue 2, 2005, Pages 105-110

  Li, Q ^a   Yu, Y Y ^a   Zhu, Z G ^a   Ji, Y B ^a   Zhang, Y ^a   Liu, B Y ^a   Chen, X H ^a   Lin, Y Z ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cell lines; Cell proliferation; Gastric cancer; Nuclear transcription factor B; Pyrrolidine dithiocarbamate

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PYRROLIDINE DITHIOCARBAMATE; PROTEIN PRECURSOR; TRANSCRIPTION FACTOR RELA;

APOPTOSIS; ARTICLE; CANCER CELL; CELL ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STOMACH CARCINOMA; WESTERN BLOTTING; ADENOCARCINOMA; CELL DIVISION; CELL NUCLEUS; FEMALE; METABOLISM; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CELL NUCLEUS; FEMALE; HUMANS; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; PROTEIN PRECURSORS; STOMACH NEOPLASMS; TRANSCRIPTION FACTOR RELA;

EID: 20844436142     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084541     Document Type: Article

References (36)

1. Chen X, Kandasamy K, Srivastava RK: Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res 2003;63:1059-1066.
2. Sun SC, Xiao G: Deregulation of NF-kappaB and its upstream kinases in cancer. Cancer Metastasis Rev 2003;22:405-422.
3. Lin A, Karin M: NF-kappaB in cancer: A marked target. Semin Cancer Biol 2003;13: 107-114.
4. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ: The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119-127.
5. Chen F, Castranova V, Shi X, Demers LM: New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999;45: 7-17.
6. Suh J, Rabson AB: NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem 2004;91:100-117.
7. Lim JW, Kim H, Kim KH: Nuclear factor-κB regulates cyclooxygenase-2 expression and cell proliferation in human gastric cancer cells. Lab Invest 2001;81:349-360.
8. Della Ragione F, Cucciolla V, Bordello A, Della Pietra V, Manna C, Galletti P, Zappia V: Pyrrolidine dithiocarbamate induces apoptosis by a cytochrome c-dependent mechanism. Biochem Biophys Res Commun 2000;268:942-946.
9. Sen R, Baltimore D: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986;46:705-716.
10. Barnes PJ, Karin M: Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336: 1066-1071.
11. Ober BT, Bruhl P, Schmidt M, Wieser V, Gritschenberger W, Coulibaly S, Savidis-Dacho H, Gerencer M, Falkner FG: Immunogenicity and safety of defective vaccinia virus lister: Comparison with modified vaccinia virus Ankara. J Virol 2002;76:7713-7723.
12. Baldwin AS Jr: Series introduction: The transcription factor NF-kappaB and human disease. J Clin Invest 2001;107:3-6.
13. Mayo MW, Baldwin AS: The transcription factor NF-kappaB: Control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 2000;1470:M55-M62.
14. Wulczyn FG, Krappmann D, Scheidereit C: The NF-κB/Rel and IκB gene families: Mediators of immune response and inflammation. J Mol Med 1996;74:749-769.
15. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr: Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997;17:3629-3639.
16. Shibata A, Nagaya T, Imai T, Funahashi H, Nakao A, Seo H: Inhibition of NF-kappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat 2002;73:237-243.
17. Bhat-Nakshatri P, Sweeney CJ, Nakshatri H: Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells. Oncogene 2002;21:2066-2078.
18. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gelinas C, Rabson AB: Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 2002;52: 183-200.
19. Ismail HA, Lessard L, Mes-Masson AM, Saad F: Expression of NF-kappaB in prostate cancer lymph node metastases. Prostate 2004;58:308-313.
20. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D: Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappaB. Nature 1995;376:167-170.
21. Sha WC, Liou HC, Tuomanen EI, Baltimore D: Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 1995;80:321-330.
22. Beg AA, Baltimore D: An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996;274:782-784.
23. Liu ZG, Hsu H, Goeddel DV, Karin M: Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 1996;87:565-576.
24. Wang CY, Mayo MW, Baldwin AS Jr: TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996;274:784-787.
25. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, Gielen J, Merville MP, Bours V: NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003;22:90-97.
26. Tergaonkar V, Bottero V, Ikawa M, Li Q, Verma IM: IkappaB kinase-independent Ikappa-Balpha degradation pathway: Functional NF-kappaB activity and implications for cancer therapy. Mol Cell Biol 2003;23:8070-8083.
27. 7 Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001;107:241-246.
28. Bharti AC, Aggarwal BB: Nuclear factor-kappa B and cancer: Its role in prevention and therapy. Biochem Pharmacol 2002;64:883-888.
29. Tamatani T, Azuma M, Ashida Y, Motegi K, Takashima R, Harada K, Kawaguchi S, Sato M: Enhanced radiosensitization and chemosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8. Int J Cancer 2004;108:912-921.
30. Fahy BN, Schlieman MG, Virudachalam S, Bold RJ: Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: Implications for therapy in pancreatic cancer. J Am Coll Surg 2004;198:591-599.
31. Muerkoster S, Arlt A, Witt M, Gehrz A, Haye S, March C, Grohmann F, Wegehenkel K, Kalthoff H, Fölsch UR, Schäfer H: Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer 2003;104:469-476.
32. Ueda M, Kokura S, Imamoto E, Naito Y, Handa O, Takagi T, Yoshida N, Yoshikawa T: Blocking of NF-kappaB activation enhances the tumor necrosis factor alpha-induced apoptosis of a human gastric cancer cell line. Cancer Lett 2003;193:177-182.
33. Uetsuka H, Haisa M, Kimura M, Gunduz M, Kaneda Y, Ohkawa T, Takaoka M, Murata T, Nobuhisa T, Yamatsuji T, Matsuoka J, Tanaka N, Naomoto Y: Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res 2003;289:27-35.
34. Orlowski RZ, Baldwin AS Jr: NF-kappaB as a therapeutic target in cancer. Trends Mol Med 2002;8:385-389.
35. Wang W, McLeod HL, Cassidy J: Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 2003; 104:504-511.
36. Bach SP, Chinery R, O'Dwyer ST, Potten CS, Coffey RJ, Watson AJ: Pyrrolidinedithiocarbamate increases the therapeutic index of 5-fluorouracil in a mouse model. Gastroenterology 2000;118:81-89.